Multiple infliximab biosimilar switches: results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry

H. Nabi, B. Glintborg, A. G. Loft, O. Hendricks, J. K. Pedersen, S. A. Just, R. Ahmed, K. Danebod, H. L. Munk, A. Colic, A. Linauskas, D. V. Jensen, L. B. Christensen, N. Manilo, N. Lomborg, S. Kristensen, F. Mehnert, N. S. Krogh, M. L. Hetland

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Original languageEnglish
Article numberOP16
JournalScandinavian Journal of Rheumatology
Issue numberSuppl. 130
Pages (from-to)14-15
Number of pages2
Publication statusPublished - Aug 2021
EventThe 38th Scandinavian Congress of Rheumatology - Ålesund, Norway
Duration: 1. Sept 20214. Sept 2022


ConferenceThe 38th Scandinavian Congress of Rheumatology

Cite this